Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Cash (2016 - 2025)

Historic Change in Cash for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $392.3 million.

  • Ocular Therapeutix's Change in Cash rose 121705.68% to $392.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $345.0 million, marking a year-over-year increase of 7586.89%. This contributed to the annual value of $345.0 million for FY2025, which is 7586.89% up from last year.
  • Per Ocular Therapeutix's latest filing, its Change in Cash stood at $392.3 million for Q4 2025, which was up 121705.68% from -$46.4 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Change in Cash high stood at $392.3 million for Q4 2025, and its period low was -$46.4 million during Q3 2025.
  • For the 5-year period, Ocular Therapeutix's Change in Cash averaged around $25.4 million, with its median value being -$16.3 million (2021).
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 19719.97% in 2021, then skyrocketed by 133348.37% in 2024.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Change in Cash stood at -$15.1 million in 2021, then decreased by 23.37% to -$18.6 million in 2022, then skyrocketed by 557.14% to $85.3 million in 2023, then crashed by 141.19% to -$35.1 million in 2024, then surged by 1217.06% to $392.3 million in 2025.
  • Its Change in Cash stands at $392.3 million for Q4 2025, versus -$46.4 million for Q3 2025 and $41.5 million for Q2 2025.